GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (ASX:IMC) » Definitions » Price-to-Funds-From-Operations

Immuron (ASX:IMC) Price-to-Funds-From-Operations : (As of Dec. 14, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Immuron Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Immuron Business Description

Industry
Traded in Other Exchanges
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.